NCT01683084

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Palo Alto Veterans Institute for Research · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.

Detailed description

Currently, the only management options for AAA are surgical (open or endovascular) based on ongoing follow-up with imaging at regular intervals. Telmisartan is currently approved for use in the United States by the Food and Drug Administration for management of hypertension. If telmisartan is found to be effective in slowing the progression of abdominal aortic aneurysms, this would provide a new treatment option for patients with AAA disease.

Conditions

• Abdominal Aortic Aneurysm

Interventions

Type	Name	Description
DRUG	Telmisartan
DRUG	Placebo

Timeline

• Start date: 2012-09-19
• Primary completion: 2018-11-10
• Completion: 2018-11-10
• First posted: 2012-09-11
• Last updated: 2020-05-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study